Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Pulmonary Hypertension, December 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 122 articles:
HTML format


 

Single Articles

  1. SANTOS-MARTINEZ LE, Orihuela-Rodriguez O, Rodriguez-Almendros NA, Carmona-Ruiz H, et al
    [The pulmonary hypertension of the chronic kidney disease].
    Rev Med Inst Mex Seguro Soc. 2017;55:621-631.
    Abstract    

    Abstract available

  2. BAR N, Schwartz LA, Biner S, Aviram G, et al
    Clinical Outcome of Isolated Tricuspid Regurgitation in Patients with Preserved Left Ventricular Ejection Fraction and Pulmonary Hypertension.
    J Am Soc Echocardiogr. 2017 Nov 28. pii: S0894-7317(17)30687.
    Abstract    

    Abstract available

  3. WALLNER M, Eaton DM, Berretta RM, Borghetti G, et al
    A Feline HFpEF Model with Pulmonary Hypertension and Compromised Pulmonary Function.
    Sci Rep. 2017;7:16587.
    Abstract    

    Abstract available

  4. YOUNG KC, Bancalari E
    Should All Extremely Premature Infants Be Screened for Pulmonary Hypertension?
    Neonatology. 2017;113:89-91.
    Abstract    



  5. KARPUZ D, Giray D, Celik Y, Hallioglu O, et al
    Prognostic Markers in Congenital Diaphragmatic Hernia: Left Ventricular Diameter and Pulmonary Hypertension.
    Pediatr Int. 2017 Nov 27. doi: 10.1111/ped.13464.
    Abstract    

    Abstract available

  6. MENG X, Li Y, Li H, Lv X, et al
    Three-dimensional echocardiography to evaluate right atrial volume and phasic function in pulmonary hypertension.
    Echocardiography. 2017 Nov 26. doi: 10.1111/echo.13761.
    Abstract    

    Abstract available

  7. HELLENKAMP K, Unsold B, Mushemi-Blake S, Shah AM, et al
    Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Assign the Likelihood of Pulmonary Hypertension.
    J Am Soc Echocardiogr. 2017 Nov 23. pii: S0894-7317(17)30686.
    Abstract    

    Abstract available

  8. DI MAURO M, Foschi M, Tancredi F, Guarracini S, et al
    Additive and independent prognostic role of abnormal right ventricle and pulmonary hypertension in mitral-tricuspid surgery.
    Int J Cardiol. 2017 Nov 14. pii: S0167-5273(17)34990.
    Abstract    



  9. PONOMAREV RV, Model SV, Averbukh OM, Gavrilov AM, et al
    [Progressive pulmonary hypertension in a patient with type 1 Gaucher disease].
    Ter Arkh. 2017;89:71-74.
    Abstract    

    Abstract available

  10. PANCIERA T, Azzolin L, Cordenonsi M, Piccolo S, et al
    Mechanobiology of YAP and TAZ in physiology and disease.
    Nat Rev Mol Cell Biol. 2017;18:758-770.
    Abstract    

    Abstract available

  11. CORBOZ MR, Li Z, Malinin V, Plaunt AJ, et al
    Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug.
    J Pharmacol Exp Ther. 2017;363:348-357.
    Abstract    

    Abstract available

  12. SUN Z, Nie X, Sun S, Dong S, et al
    Long Non-Coding RNA MEG3 Downregulation Triggers Human Pulmonary Artery Smooth Muscle Cell Proliferation and Migration via the p53 Signaling Pathway.
    Cell Physiol Biochem. 2017;42:2569-2581.
    Abstract    

    Abstract available

  13. MALACZYNSKA-RAJPOLD K
    Response to the comment on the article entitled "Balloon atrial septostomy in pulmonary arterial hypertension: A beneficial effect on the control of rhythm abnormalities".
    Cardiol J. 2017;24:457.
    Abstract    



  14. SABINIEWICZ R
    Baloon atrial septostomy in pulmonary arterial hypertension: Atrial flow regulator - New therapeutic option.
    Cardiol J. 2017;24:455-456.
    Abstract    



  15. NEGOI RI, Ghiorghiu I, Filipoiu F, Hostiuc M, et al
    Severe pulmonary arterial hypertension associated with congenital cardiac shunts: evolution under specific treatment.
    J Med Life. 2017;10:131-138.
    Abstract    

    Abstract available

  16. SARSAM S, Kaspar G, David S, Zughaib M, et al
    Early Detection of Subclinical Aortic Valve Endocarditis with the CardioMEMS Heart Failure System.
    Am J Case Rep. 2017;18:665-668.
    Abstract    

    Abstract available

  17. SHAPIRO S, Torres F, Feldman J, Keogh A, et al
    Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Respir Med. 2017;126:84-92.
    Abstract    

    Abstract available

  18. FERREIRA JC, Patino CM
    Types of outcomes in clinical research.
    J Bras Pneumol. 2017;43:5.
    Abstract    



  19. COSTE F, Guibert C, Magat J, Abell E, et al
    Chronic hypoxia aggravates monocrotaline-induced pulmonary arterial hypertension: a rodent relevant model to the human severe form of the disease.
    Respir Res. 2017;18:47.
    Abstract    

    Abstract available

  20. XU Y, Gu Q, Qu C
    Capsaicin pretreatment reversed pulmonary arterial hypertension by alleviating inflammation via p38MAPK pathway.
    Exp Lung Res. 2017;43:8-18.
    Abstract    

    Abstract available

  21. GALIE N, Denton CP, Dardi F, Manes A, et al
    Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
    Int J Cardiol. 2017;235:67-72.
    Abstract    

    Abstract available

  22. DUO-JI MM, Long ZW
    Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
    Int J Cardiol. 2017;234:90-98.
    Abstract    

    Abstract available

  23. WILD B, St-Pierre ME, Langlois S, Cowan KN, et al
    Elastase and matrix metalloproteinase activities are associated with pulmonary vascular disease in the nitrofen rat model of congenital diaphragmatic hernia.
    J Pediatr Surg. 2017 Jan 27. pii: S0022-3468(17)30042.
    Abstract    

    Abstract available

  24. ZIMMER J, Takahashi T, Hofmann AD, Puri P, et al
    Downregulation of KCNQ5 expression in the rat pulmonary vasculature of nitrofen-induced congenital diaphragmatic hernia.
    J Pediatr Surg. 2017 Jan 26. pii: S0022-3468(17)30048.
    Abstract    

    Abstract available

  25. GONZALEZ-SAIZ L, Fiuza-Luces C, Sanchis-Gomar F, Santos-Lozano A, et al
    Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial.
    Int J Cardiol. 2017;231:277-283.
    Abstract    

    Abstract available

  26. GHIO S, D'Alto M, Badagliacca R, Vitulo P, et al
    Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension.
    Int J Cardiol. 2017;230:53-58.
    Abstract    

    Abstract available

  27. JACOB SA, Novelli EM, Isenberg JS, Garrett ME, et al
    Thrombospondin-1 Gene Polymorphism is Associated with Estimated Pulmonary Artery Pressure in Patients with Sickle Cell Anemia.
    Am J Hematol. 2016 Dec 29. doi: 10.1002/ajh.24635.
    Abstract    



  28. XU T, Liu S, Ma T, Jia Z, et al
    Aldehyde dehydrogenase 2 protects against oxidative stress associated with pulmonary arterial hypertension.
    Redox Biol. 2017;11:286-296.
    Abstract    

    Abstract available

  29. FARMAKIS D, Triposkiadis F, Lekakis J, Parissis J, et al
    Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management.
    Eur J Heart Fail. 2016 Dec 20. doi: 10.1002.
    Abstract    

    Abstract available

  30. MATHAI SC, Minai O, Sullivan SD, Lerner D, et al
    Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatment.
    Respir Med. 2017;122 Suppl 1:S23-S27.
    Abstract    

    Abstract available

  31. HOEPER MM, Klinger JR, Benza RL, Simonneau G, et al
    Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Respir Med. 2017;122 Suppl 1:S18-S22.
    Abstract    

    Abstract available

  32. GRIFFIN M, Trow TK
    The evolving landscape of combination therapy for pulmonary arterial hypertension.
    Ther Adv Respir Dis. 2017;11:91-95.
    Abstract    

    Abstract available

  33. HOEPER MM, McLaughlin VV, Barbera JA, Frost AE, et al
    Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
    Lancet Respir Med. 2016;4:894-901.
    Abstract    

    Abstract available

  34. DISTLER O, Pope J, Denton C, Allanore Y, et al
    RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Respir Med. 2017;122 Suppl 1:S14-S17.
    Abstract    

    Abstract available

  35. HAHN SS, Makaryus M, Talwar A, Narasimhan M, et al
    A review of therapeutic agents for the management of pulmonary arterial hypertension.
    Ther Adv Respir Dis. 2017;11:46-63.
    Abstract    

    Abstract available

  36. BURGOS CM, Pearson EG, Davey M, Riley J, et al
    Improved pulmonary function in the nitrofen model of congenital diaphragmatic hernia following prenatal maternal dexamethasone and/or sildenafil.
    Pediatr Res. 2016 Jul 4. doi: 10.1038/pr.2016.
    Abstract    

    Abstract available

  37. EDAHIRO Y, Takaku T, Konishi H, Tsukune Y, et al
    [Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].
    Rinsho Ketsueki. 2017;58:2213-2218.
    Abstract    

    Abstract available

  38. CHRISTOU H, Hudalla H, Michael Z, Filatava E, et al
    Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in Sugen-Hypoxia Rat Model.
    J Pharmacol Exp Ther. 2017 Dec 6. pii: jpet.117.244798.
    Abstract    

    Abstract available

  39. BERGHAUS TM, Kutsch J, Faul C, von Scheidt W, et al
    The association of N-terminal pro-brain-type natriuretic peptide with hemodynamics and functional capacity in therapy-naive precapillary pulmonary hypertension: results from a cohort study.
    BMC Pulm Med. 2017;17:167.
    Abstract    

    Abstract available

  40. WANG L, Jin YZ, Zhao QH, Jiang R, et al
    Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension.
    Int J Chron Obstruct Pulmon Dis. 2017;12:3353-3360.
    Abstract    

    Abstract available

  41. COONS JC, Bunner C, Ishizawar DC, Risbano MG, et al
    Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension.
    Pulm Circ. 2018;8:2045893217744512.
    Abstract    

    Abstract available

  42. WARRICKER F, Islam Z, Shah BN
    Lesson of the month 1: Obesity hypoventilation (Pickwickian) syndrome: a reversible cause of severe pulmonary hypertension.
    Clin Med (Lond). 2017;17:578-581.
    Abstract    

    Abstract available

  43. CONNOLLY MJ, Abdullah S, Ridout DA, Schreiber BE, et al
    Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension.
    Rheumatology (Oxford). 2017;56:2197-2203.
    Abstract    

    Abstract available

  44. VALIEVA ZS, Martynyuk TV, Chazova IE
    [Bosentan use in pulmonary arterial hypertension: Russian and foreign experience].
    Ter Arkh. 2017;89:95-103.
    Abstract    

    Abstract available

  45. KING CS, Roy A, Ryan L, Singh R, et al
    Cardiac Support: Emphasis on Venoarterial ECMO.
    Crit Care Clin. 2017;33:777-794.
    Abstract    

    Abstract available

  46. ALVAREZ RA, Miller MP, Hahn SA, Galley JC, et al
    Targeting Pulmonary Endothelial Hemoglobin alpha Improves Nitric Oxide Signaling and Reverses Pulmonary Artery Endothelial Dysfunction.
    Am J Respir Cell Mol Biol. 2017;57:733-744.
    Abstract    

    Abstract available

  47. GORBACHEVSKY SV, Shmalts AA, Barishnikova IY, Zaets SB, et al
    Potts shunt in children with pulmonary arterial hypertension: institutional experience.
    Interact Cardiovasc Thorac Surg. 2017;25:595-599.
    Abstract    

    Abstract available

  48. PENA A, Kobir A, Goncharov D, Goda A, et al
    Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.
    Am J Respir Cell Mol Biol. 2017;57:615-625.
    Abstract    

    Abstract available

  49. KOJONAZAROV B, Novoyatleva T, Boehm M, Happe C, et al
    p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy.
    Am J Respir Cell Mol Biol. 2017;57:603-614.
    Abstract    

    Abstract available

  50. SANKHE S, Manousakidi S, Antigny F, Arthur Ataam J, et al
    T-type Ca(2+) channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension.
    Biochim Biophys Acta. 2017;1864:1631-1641.
    Abstract    

    Abstract available

  51. AXELL RG, Messer SJ, White PA, McCabe C, et al
    Ventriculo-arterial coupling detects occult RV dysfunction in chronic thromboembolic pulmonary vascular disease.
    Physiol Rep. 2017;5.
    Abstract    

    Abstract available

  52. LUITEL H, Sydykov A, Schymura Y, Mamazhakypov A, et al
    Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle.
    Physiol Rep. 2017;5.
    Abstract    

    Abstract available

  53. ROL N, Timmer EM, Faes TJ, Vonk Noordegraaf A, et al
    Vascular narrowing in pulmonary arterial hypertension is heterogeneous: rethinking resistance.
    Physiol Rep. 2017;5.
    Abstract    

    Abstract available

  54. SCHEY C, Krabbe PF, Postma MJ, Connolly MP, et al
    Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs.
    Orphanet J Rare Dis. 2017;12:10.
    Abstract    

    Abstract available

  55. MONTANI D, Girerd B, Jais X, Levy M, et al
    Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.
    Lancet Respir Med. 2017;5:125-134.
    Abstract    

    Abstract available

  56. HUMMLER JK, Dapaah-Siakwan F, Vaidya R, Zambrano R, et al
    Inhibition of Rac1 Signaling Downregulates Inflammasome Activation and Attenuates Lung Injury in Neonatal Rats Exposed to Hyperoxia.
    Neonatology. 2017;111:280-288.
    Abstract    

    Abstract available

  57. ONG SB, Hausenloy DJ
    Mitochondrial Dynamics as a Therapeutic Target for Treating Cardiac Diseases.
    Handb Exp Pharmacol. 2017;240:251-279.
    Abstract    

    Abstract available

  58. KING CS, Nathan SD
    Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities.
    Lancet Respir Med. 2017;5:72-84.
    Abstract    

    Abstract available

  59. GHOFRANI HA, Grimminger F, Grunig E, Huang Y, et al
    Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
    Lancet Respir Med. 2016 Apr 8. pii: S2213-2600(16)30019.
    Abstract    

    Abstract available

  60. PLOEGSTRA MJ, Ivy DD, Wheeler JG, Brand M, et al
    Growth in children with pulmonary arterial hypertension: a longitudinal retrospective multiregistry study.
    Lancet Respir Med. 2016 Mar 16. pii: S2213-2600(16)00069.
    Abstract    

    Abstract available

  61. LAJOIE AC, Lauziere G, Lega JC, Lacasse Y, et al
    Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.
    Lancet Respir Med. 2016 Feb 26. pii: S2213-2600(16)00027.
    Abstract    

    Abstract available

  62. BHASIN S, Gogia P, Nair R, Sahoo TK, et al
    Perioperative sildenafil therapy for children with ventricular septal defects and associated pulmonary hypertension undergoing corrective surgery: A randomised clinical trial.
    Indian J Anaesth. 2017;61:798-802.
    Abstract    

    Abstract available

  63. KLEVANETS IE, Karpenko AA, Shilova AN
    [Use of local thrombolysis in patients with massive pulmonary thromboembolism and moderate-to-severe pulmonary hypertension].
    Angiol Sosud Khir. 2017;23:7-12.
    Abstract    

    Abstract available

  64. TANAKA Y, Hino M, Gemma A
    Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study.
    BMC Pulm Med. 2017;17:200.
    Abstract    

    Abstract available

  65. JACOB J, Bartholmai BJ, Rajagopalan S, Karwoski R, et al
    Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema.
    Respirology. 2017 Dec 13. doi: 10.1111/resp.13231.
    Abstract    

    Abstract available

  66. HOFFMANN-VOLD AM, Fretheim H, Midtvedt O, Kilian K, et al
    Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort.
    Rheumatology (Oxford). 2017 Dec 11. pii: 4719306.
    Abstract    

    Abstract available

  67. AKBAL OY, Kaymaz C, Tanboga IH, Hakgor A, et al
    Extrinsic compression of left main coronary artery by aneurysmal pulmonary artery in severe pulmonary hypertension: its correlates, clinical impact, and management strategies.
    Eur Heart J Cardiovasc Imaging. 2017 Dec 8. pii: 4717459.
    Abstract    

    Abstract available

  68. MERTENS LL
    Right Atrial Contractile Function in Pediatric Pulmonary Hypertension: A Novel Marker for Disease Severity?
    Circ Cardiovasc Imaging. 2017;10.
    Abstract    



  69. JONE PN, Schafer M, Li L, Craft M, et al
    Right Atrial Deformation in Predicting Outcomes in Pediatric Pulmonary Hypertension.
    Circ Cardiovasc Imaging. 2017;10.
    Abstract    

    Abstract available

  70. SCHNEIDER M, Pistritto AM, Gerges C, Gerges M, et al
    Multi-view approach for the diagnosis of pulmonary hypertension using transthoracic echocardiography.
    Int J Cardiovasc Imaging. 2017 Dec 11. pii: 10.1007/s10554-017-1279.
    Abstract    

    Abstract available

  71. WANG YC, Huang CH, Tu YK
    Pulmonary Hypertension and Pulmonary Artery Acceleration Time: A Systematic Review and Meta-Analysis.
    J Am Soc Echocardiogr. 2017 Dec 8. pii: S0894-7317(17)30733.
    Abstract    

    Abstract available

  72. BOUCHERY-BARDET H, Creveuil C, Bauer F, Beygui F, et al
    Heart rate and risk of death among patients with Pulmonary Hypertension: A 12-lead ECG analysis.
    Respir Med. 2017;132:42-49.
    Abstract    

    Abstract available

  73. BALKO R, Edriss H, Nugent K, Test V, et al
    Pulmonary veno-occlusive disease: An important consideration in patients with pulmonary hypertension.
    Respir Med. 2017;132:203-209.
    Abstract    

    Abstract available

  74. ZHOU Y, Wang Y, Wang X, Tian X, et al
    The Protective Effects of Kappa-Opioid Receptor Stimulation in Hypoxic Pulmonary Hypertension Involve Inhibition of Autophagy Through the AMPK-MTOR Pathway.
    Cell Physiol Biochem. 2017;44:1965-1979.
    Abstract    

    Abstract available

  75. WILLEN SM, Gladwin MT
    What is the role of screening for pulmonary hypertension in adults and children with sickle cell disease?
    Hematology Am Soc Hematol Educ Program. 2017;2017:431-434.
    Abstract    

    Abstract available

  76. ZHANG N, Dong M, Luo Y, Zhao F, et al
    Danshensu prevents hypoxic pulmonary hypertension in rats by inhibiting the proliferation of pulmonary artery smooth muscle cells via TGF-beta-smad3-associated pathway.
    Eur J Pharmacol. 2017 Dec 5. pii: S0014-2999(17)30794.
    Abstract    

    Abstract available

  77. BIGNA JJ, Noubiap JJ, Nansseu JR, Aminde LN, et al
    Prevalence and etiologies of pulmonary hypertension in Africa: a systematic review and meta-analysis.
    BMC Pulm Med. 2017;17:183.
    Abstract    

    Abstract available

  78. GO YY, Dulgheru R, Sugimoto T, Marchetta S, et al
    Exercise Doppler echocardiography for the diagnosis of pulmonary hypertension: renewed interest and evolving roles.
    J Thorac Dis. 2017;9:2856-2861.
    Abstract    



  79. ZIVANOVIC S, Pushparajah K, Calvert S, Marlow N, et al
    Pulmonary Artery Pressures in School-Age Children Born Prematurely.
    J Pediatr. 2017;191:42-49.
    Abstract    

    Abstract available

  80. GAO W, Shao R, Zhang X, Liu D, et al
    Up-regulation of caveolin-1 by DJ-1 attenuates rat pulmonary arterial hypertension by inhibiting TGFbeta/Smad signaling pathway.
    Exp Cell Res. 2017;361:192-198.
    Abstract    

    Abstract available

  81. JAFRI S, Ormiston ML
    Immune regulation of systemic hypertension, pulmonary arterial hypertension, and preeclampsia: shared disease mechanisms and translational opportunities.
    Am J Physiol Regul Integr Comp Physiol. 2017;313:R693-R705.
    Abstract    

    Abstract available

  82. YIU KH, Chen Y, Liu JH, Lin Q, et al
    Burden and contributing factors associated with tricuspid regurgitation: a hospital-based study.
    Hosp Pract (1995). 2017;45:209-214.
    Abstract    

    Abstract available

  83. CHEN D, Gao W, Wang S, Ni B, et al
    Critical effects of epigenetic regulation in pulmonary arterial hypertension.
    Cell Mol Life Sci. 2017;74:3789-3808.
    Abstract    

    Abstract available

  84. ONAL EM, Sag AA, Sal O, Yerlikaya A, et al
    Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension.
    Clin Exp Hypertens. 2017;39:197-209.
    Abstract    

    Abstract available

  85. JOHAR D
    Cytoskeletal remodeling and regulation of cell fate in the hypertensive neonatal pulmonary artery in response to stress.
    J Cell Physiol. 2018;233:2146-2161.
    Abstract    

    Abstract available

  86. ADAMS DS, Marolf AJ, Valdes-Martinez A, Randall EK, et al
    Associations between thoracic radiographic changes and severity of pulmonary arterial hypertension diagnosed in 60 dogs via Doppler echocardiography: A retrospective study.
    Vet Radiol Ultrasound. 2017;58:454-462.
    Abstract    

    Abstract available

  87. SCHWARZ EI, Vrugt B, Huber LC, Murer C, et al
    Development of Allograft Cancer after Lung Transplantation: A Case Report.
    Ann Thorac Cardiovasc Surg. 2017 Mar 29. doi: 10.5761/atcs.cr.16-00221.
    Abstract    

    Abstract available

  88. ZHAO J, Wang Q, Liu Y, Tian Z, et al
    Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China.
    Int J Cardiol. 2017;236:432-437.
    Abstract    

    Abstract available

  89. BAILLIE TJ, Sidharta S, Steele PM, Worthley SG, et al
    The predictive capabilities of a novel cardiovascular magnetic resonance derived marker of cardiopulmonary reserve on established prognostic surrogate markers in patients with pulmonary vascular disease: results of a longitudinal pilot study.
    J Cardiovasc Magn Reson. 2017;19:3.
    Abstract    

    Abstract available

  90. WANG X, Wang Y, Zhang J, Guan X, et al
    Galectin-3 contributes to vascular fibrosis in monocrotaline-induced pulmonary arterial hypertension rat model.
    J Biochem Mol Toxicol. 2017;31.
    Abstract    

    Abstract available

  91. MUMBY S, Gambaryan N, Meng C, Perros F, et al
    Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension.
    Respirology. 2017;22:157-164.
    Abstract    

    Abstract available

  92. MORRIS NR, Seale H, Harris J, Hall K, et al
    Gas exchange responses during 6-min walk test in patients with pulmonary arterial hypertension.
    Respirology. 2017;22:165-171.
    Abstract    

    Abstract available

  93. LI W, Yang T, Zhang Y, Gu Q, et al
    Prognostic value of right ventricular ejection/filling parameters in IPAH using cardiac magnetic resonance: A prospective pilot study.
    Respirology. 2017;22:172-178.
    Abstract    

    Abstract available

  94. KHAIRA K, Allen R, Amsterdam EA
    A diagnosis at hand: pulmonary arterial hypertension.
    Am J Med. 2016 May 3. pii: S0002-9343(16)30443.
    Abstract    



  95. TANNENBERG P, Chang YT, Muhl L, Lavina B, et al
    Extracellular Retention of PDGF-B Directs Vascular Remodeling in Mouse Hypoxia-induced Pulmonary Hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2017 Dec 6:ajplung.00054.2017.
    Abstract    

    Abstract available

  96. KATO F, Sakao S, Takeuchi T, Suzuki T, et al
    Endothelial cell-related autophagic pathways in Sugen/hypoxia-exposed pulmonary arterial hypertensive rats.
    Am J Physiol Lung Cell Mol Physiol. 2017;313:L899-L915.
    Abstract    

    Abstract available

  97. YUN X, Jiang H, Lai N, Wang J, et al
    Aquaporin 1-mediated changes in pulmonary arterial smooth muscle cell migration and proliferation involve beta-catenin.
    Am J Physiol Lung Cell Mol Physiol. 2017;313:L889-L898.
    Abstract    

    Abstract available

  98. MARON BA, Wertheim BM, Gladwin MT
    Under Pressure to Clarify Pulmonary Hypertension Clinical Risk.
    Am J Respir Crit Care Med. 2017 Dec 7. doi: 10.1164/rccm.201711-2306.
    Abstract    



  99. MATHAI SC, Kawut SM
    Magnetic Resonance Imaging in Pulmonary Arterial Hypertension. Panacea or Pixelation?
    Am J Respir Crit Care Med. 2017;196:129-131.
    Abstract    



  100. AUSTIN ED, Feinstein JA
    Accelerometry: Improving Objective Assessments of Therapeutic Impact in Pediatric Pulmonary Arterial Hypertension.
    Am J Respir Crit Care Med. 2017;196:127-129.
    Abstract    



  101. CHUN HJ, Bonnet S, Chan SY
    Reply: Transforming Growth Factor beta1- and Bone Morphogenetic Protein 2/PPARgamma-regulated MicroRNAs in Pulmonary Arterial Hypertension.
    Am J Respir Crit Care Med. 2017;196:1228-1229.
    Abstract    



  102. CALVIER L, Chouvarine P, Legchenko E, Hansmann G, et al
    Transforming Growth Factor beta1- and Bone Morphogenetic Protein 2/PPARgamma-regulated MicroRNAs in Pulmonary Arterial Hypertension.
    Am J Respir Crit Care Med. 2017;196:1227-1228.
    Abstract    



  103. HAMID R, Yan L
    Induced Pluripotent Stem Cells in Pulmonary Arterial Hypertension.
    Am J Respir Crit Care Med. 2017;195:852-853.
    Abstract    



  104. GUPTE SA, Wolin MS
    Mitochondrial Calcium Transport: A Potentially Prominent, Therapeutically Targetable Contributor to Pulmonary Arterial Hypertension Progression.
    Am J Respir Crit Care Med. 2017;195:420-421.
    Abstract    



  105. BAILLIE TJ, Sidharta S, Steele PM, Worthley SG, et al
    Noninvasive Assessment of Cardiopulmonary Reserve: Toward Early Detection of Pulmonary Vascular Disease.
    Am J Respir Crit Care Med. 2017;195:398-401.
    Abstract    



  106. LEBERKUHNE LJ, Ploegstra MJ, Douwes JM, Bartelds B, et al
    Serially Measured Uric Acid Levels Predict Disease Severity and Outcome in Pediatric Pulmonary Arterial Hypertension.
    Am J Respir Crit Care Med. 2017;195:401-404.
    Abstract    



  107. LAHM T, Frump AL
    Toward Harnessing Sex Steroid Signaling as a Therapeutic Target in Pulmonary Arterial Hypertension.
    Am J Respir Crit Care Med. 2017;195:284-286.
    Abstract    



  108. BRUSSELLE G, Bracke K, De Pauw M
    Peripheral Artery Disease in Patients with Chronic Obstructive Pulmonary Disease.
    Am J Respir Crit Care Med. 2017;195:148-150.
    Abstract    



  109. BONNET S, Provencher S, Guignabert C, Perros F, et al
    Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.
    Am J Respir Crit Care Med. 2017;195:583-595.
    Abstract    



  110. MIHAI C, Antic M, Dobrota R, Bonderman D, et al
    Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.
    Ann Rheum Dis. 2018;77:128-132.
    Abstract    

    Abstract available

  111. HILL NS, Gillespie MN, McMurtry IF
    Fifty Years of Monocrotaline-Induced Pulmonary Hypertension: What Has It Meant to the Field?
    Chest. 2017;152:1106-1108.
    Abstract    



  112. HADINNAPOLA C, Bleda M, Haimel M, Screaton N, et al
    Phenotypic Characterisation of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically with Pulmonary Arterial Hypertension.
    Circulation. 2017 Sep 28. pii: CIRCULATIONAHA.117.028351.
    Abstract    

    Abstract available

  113. SAITO T, Miyagawa K, Chen SY, Tamosiuniene R, et al
    Upregulation of HERV-K is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension.
    Circulation. 2017 Sep 21. pii: CIRCULATIONAHA.117.027589.
    Abstract    

    Abstract available

  114. RAMADAN ME, Shabsigh M, Awad H
    Con: Inhaled Pulmonary Vasodilators Are Not Indicated in Patients Undergoing Lung Transplantation.
    J Cardiothorac Vasc Anesth. 2016 Aug 31. pii: S1053-0770(16)30374.
    Abstract    



  115. BIANCO JC, Mc Loughlin S, Denault AY, Marenchino RG, et al
    Heart Transplantation in Patients >/=60 Years: Importance of Relative Pulmonary Hypertension and Right Ventricular Failure on Midterm Survival.
    J Cardiothorac Vasc Anesth. 2017 Sep 18. pii: S1053-0770(17)30756.
    Abstract    

    Abstract available

  116. BOLLIGER D, Bouchez S, Mauermann E
    Re-examining Factors Associated With Mortality After Heart Transplantation: A Focus on Recipient Age and Relative Pulmonary Hypertension.
    J Cardiothorac Vasc Anesth. 2017 Nov 4. pii: S1053-0770(17)30882.
    Abstract    



  117. CAMPOS C, Luz de Castro A, Vicente Tavares AM, Fernandes RO, et al
    Effect of free and nanoencapsulated copaiba oil on monocrotaline-induced pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2016.
    Abstract    

    Abstract available

  118. SURESH G, King BC, Jain SK
    Screening for pulmonary hypertension in preterm infants-not ready for prime time.
    J Perinatol. 2017 Nov 27. pii: 10.1038/s41372-017-0014.
    Abstract    



  119. ALTIT G, Lee HC, Hintz S, Tacy TA, et al
    Practices surrounding pulmonary hypertension and bronchopulmonary dysplasia amongst neonatologists caring for premature infants.
    J Perinatol. 2017 Dec 12. pii: 10.1038/s41372-017-0025.
    Abstract    

    Abstract available

  120. PRICE LC, Dimopoulos K, Marino P, Alonso-Gonzalez R, et al
    The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension.
    Thorax. 2017;72:1035-1045.
    Abstract    

    Abstract available

  121. GHIO S, Crimi G, Pica S, Temporelli PL, et al
    Persistent abnormalities in pulmonary arterial compliance after heart transplantation in patients with combined post-capillary and pre-capillary pulmonary hypertension.
    PLoS One. 2017;12:e0188383.
    Abstract    

    Abstract available

  122. LOPEZ-MESEGUER M, Quezada CA, Ramon MA, Lazaro M, et al
    Lung and heart-lung transplantation in pulmonary arterial hypertension.
    PLoS One. 2017;12:e0187811.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Pulmonary Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;